Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Zentralblatt Fur Chirurgie
|
March 3, 2011
[Immediate radical re-resection of incidental T1b gallbladder cancer and the problem of an adequate extent of resection (results of the German Registry "Incidental Gallbladder Cancer")]
T O Goetze, V Paolucci
Surgical Endoscopy
|
February 6, 2008
Immediate re-resection of T1 incidental gallbladder carcinomas: a survival analysis of the German Registry
T O Goetze, V Paolucci
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|
September 6, 2013
[Incidental T1b-T3 gallbladder carcinoma. Extended cholecystectomy as an underestimated prognostic factor-results of the German registry]
T O Goetze, V Paolucci
ESMO Gastrointestinal Oncology
|
February 6, 2026
New perspectives in biliary tract cancers
T O Goetze, C Roderburg, F W Friedrich, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
SAGA-a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinoma
B Kobitzsch, G Stocker, U T Hacker, et al.
ESMO Gastrointestinal Oncology
|
April 30, 2026
UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA)
G Stocker, U T Hacker, R Lordick Obermannová, et al.
BMC Cancer
|
October 25, 2019
Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study
L Perkhofer, A W Berger, A K Beutel, et al.
ESMO Open
|
September 24, 2023
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology
S-E Al-Batran, D W Mueller, M-R Rafiyan, et al.
ESMO Open
|
August 5, 2025
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial
D Melisi, T Macarulla, C De La Fouchardière, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Zentralblatt Fur Chirurgie
|
March 3, 2011
[Immediate radical re-resection of incidental T1b gallbladder cancer and the problem of an adequate extent of resection (results of the German Registry "Incidental Gallbladder Cancer")]
T O Goetze, V Paolucci
Surgical Endoscopy
|
February 6, 2008
Immediate re-resection of T1 incidental gallbladder carcinomas: a survival analysis of the German Registry
T O Goetze, V Paolucci
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen
|
September 6, 2013
[Incidental T1b-T3 gallbladder carcinoma. Extended cholecystectomy as an underestimated prognostic factor-results of the German registry]
T O Goetze, V Paolucci
ESMO Gastrointestinal Oncology
|
February 6, 2026
New perspectives in biliary tract cancers
T O Goetze, C Roderburg, F W Friedrich, et al.
ESMO Gastrointestinal Oncology
|
February 6, 2026
SAGA-a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinoma
B Kobitzsch, G Stocker, U T Hacker, et al.
ESMO Gastrointestinal Oncology
|
April 30, 2026
UCCL-IKF-AIO-STO-0124 NeoART-an international phase Ib/II platform trial investigating trastuzumab deruxtecan (T-DXd) combined with neoadjuvant chemotherapy for HER2-positive, resectable esophagogastric adenocarcinoma (EGA)
G Stocker, U T Hacker, R Lordick Obermannová, et al.
BMC Cancer
|
October 25, 2019
Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study
L Perkhofer, A W Berger, A K Beutel, et al.
ESMO Open
|
September 24, 2023
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology
S-E Al-Batran, D W Mueller, M-R Rafiyan, et al.
ESMO Open
|
August 5, 2025
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial
D Melisi, T Macarulla, C De La Fouchardière, et al.
Page
of 1